360Dx

Quest Diagnostics Q3 Revenues Rise 2 Percent, Miss Analyst Estimates

Oct 23, 2018

NEW YORK (360Dx) – Quest Diagnostics today reported 2 percent year-over-year revenue growth for the third quarter missing analyst expectations.

Revenue was $1.89 billion for the three- month period ended Sept. 30, 2018, up from $1.86 billion in the third quarter last year. The consensus Wall Street estimate was $1.95 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Quest Diagnostics Q3 Revenues Rise 2 Percent, Miss Analyst Estimates

To read the full story....

Breaking News

LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Featured White Papers

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

FDA Grants First ASCA Accreditations to Labs to Perform Premarket Testing

Sponsorships